Myriad Genetics Inc (MYGN)

MYGN (NASDAQ:Diversified Services)
$36.96
neg -1.04
-2.74%
Today's Range: 36.70 - 38.38 | MYGN Avg Daily Volume: 783,500
Last Update: 10/24/14 - 4:00 PM EDT
Volume: 443,337
YTD Performance: 81.12%
Open: $38.35
Previous Close: $38.00
52 Week Range: $20.02 - $42.50
Oustanding Shares: 72,795,117
Market Cap: 2,744,723,973
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 6 6 7 8
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.67 2.67 2.69 2.71
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.71
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
16.71 16.70 27.71
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.98% 49.67% 89.15%
GROWTH 12 Mo 3 Yr CAGR
Revenue 26.90 0.94 0.24
Net Income 19.80 0.75 0.20
EPS 27.60 1.08 0.27
Earnings for MYGN:
EBITDA 0.29B
Revenue 0.78B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (06/15) FY (06/16)
Average Estimate $0.34 $0.45 $1.88 $2.20
Number of Analysts 8 7 10 5
High Estimate $0.47 $0.51 $2.04 $2.60
Low Estimate $0.25 $0.37 $1.60 $1.84
Prior Year $0.68 $0.66 $2.43 $1.88
Growth Rate (Year over Year) -49.63% -31.39% -22.67% 17.30%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Robert Moreno

 | Oct 2, 2014 | 2:17 PM EDT

Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.

bullishMyriad Genetics price target bumped at Jefferies

Apr 2, 2014 | 8:16 AM EDT

MYGN raised its number, Jefferies said. Driven by unexpected boost to BRCA pricing. $33 price target. 

bullishMyriad Genetics upgraded at Credit Suisse

Feb 7, 2014 | 8:25 AM EST

MYGN was upgraded from Underperform to Neutral, Credit Suisse said. $29 price target. Base business can hold up better than expected and the Crescendo purchase should add to growth. 

bullishMyriad Genetics upgraded at JMP

Feb 5, 2014 | 7:58 AM EST

MYGN was upgraded from Underperform to Market Perform, JMP Securities said. Company is executing well, despite increased competition. 

bearishMyriad Genetics downgraded at JMP

Dec 30, 2013 | 7:41 AM EST

MYGN was downgraded from Market Perform to Underperform, JMP Securities said. $15 price target. BRCA pricing is lower than expected. 

bearishMyriad Genetics downgraded at JMP

Dec 3, 2013 | 8:16 AM EST

MYGN was downgraded from Outperform to Market Perform, JMP Securities said. Company could face lower reimbursement levels.

bearishMyriad Genetics downgraded at Credit Suisse

Oct 21, 2013 | 8:02 AM EDT

MYGN was downgraded from Neutral to Underperform, Credit Suisse said. $20 price target. Company is facing increased competition. 

bearishMyriad Genetics downgraded at Leerink Swann

Jun 14, 2013 | 8:40 AM EDT

MYGN was downgraded to Market Perform after a mixed ruling on gene patents, said Leerink Swann. With focus turning to cancer testing, share and pricing will be pressured. The new price target is $39.

bearishMyriad Genetics estimates lowered at Credit Suisse

Jun 14, 2013 | 8:35 AM EDT

MYGN earnings estimates were lowered on the gene-patent case ruling, Credit Suisse said. SCOTUS upheld cDNA's patent eligibility, yet competition is expected to increase. 

bearishMyriad downgraded at Jefferies

May 31, 2013 | 7:08 AM EDT

MYGN was downgraded from Buy to Hold, Jefferies said. $31 price target. Stock is up moer than 20%, ahead of the pending Supreme Court decision. 

GS has cleared the important hurdle on the way up which increases the odds for an eventual...
A good quarterly report has sent shares of Calamos Asset Management (CLMS) sharply higher....
Electronics distributor Ingram Micro (IM) reported better than 16% growth in its Q3 sendin...
Market posting decent day considering Ebola getting headlines again. Believe investors ha...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.